• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
162588 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
/ r' }- J; R9 B% d' q1 t
: t2 X1 P" P2 g0 O4 D7 b( N! ]2 z* q, P0 W
Sub-category:* J- P5 M! r' q/ C  V% s
Molecular Targets
7 o6 R2 K8 D3 |6 \% J; d) Y
$ q4 `; y, q" s* n# \
- a4 F) d  |' U! ?' G3 e8 uCategory:
$ r; h5 J# T0 g$ {Tumor Biology
' `8 m+ f) {+ k7 u2 Z- O! X, W' u0 c( ^/ d' {$ w' `

+ d+ |( w  W. ~9 Y/ X! ~Meeting:) {8 P' l6 q# F+ `' E
2011 ASCO Annual Meeting " \: K8 O2 A2 g3 r. |

4 x6 n0 ?% F. v" z. m4 y9 F5 w+ a# ^! K( E' ^
Session Type and Session Title:
- C6 C) U) u5 k0 y) j3 aPoster Discussion Session, Tumor Biology 9 R( W2 J, n) F! X4 Z
* S8 x' u+ W7 v) k
  m( G/ p# _. Z8 p/ u
Abstract No:
. F% E0 q/ L7 z% F4 s/ B& ~, a10517
& |/ }" g  i" Q  O3 d
( _' h" C: x6 V+ L" c1 B+ ^
' T, N" C4 Q4 {Citation:
/ H5 f7 w" w( I( g; R6 F) bJ Clin Oncol 29: 2011 (suppl; abstr 10517) 9 E2 \& b( }" ~

, f9 K2 s( |" M# `; J) F1 U+ u* |2 e! U0 C
Author(s):
. g6 `' M- h% `3 r( A' V" yJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China # _/ \6 }) {0 ~* Y* H6 O5 }% x
, `/ v! n9 r: U& I; ]

8 c8 f2 j' j. `' {, g. R, F5 m4 o9 M$ ]5 F) y, L' s
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.: L0 k1 U8 O; U' y) V/ M" H5 `
0 L- O/ d. M$ V& }+ N- H) ~# i
Abstract Disclosures
0 z* q$ A' q) v' B) t& l# x# |( h0 R5 w! q  N' H& e' F
Abstract:
# h8 T2 U; u& E- [% y- q
5 E1 z( A& R  v' i+ K
! g0 Q4 Q8 R4 J' o) l. ]# @Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.5 |( h6 H. J8 _$ ?$ g( V
" f# u7 D( r8 g# H4 A9 U3 o
3 ~! @! x4 E# D" V
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
* ~! j( d$ \) T' s9 M5 y没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

+ e1 w1 R/ f8 A8 r9 j化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 5 W1 F" u. g- q- b' B& L
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。; K2 _5 ^* `( z) F  J' i9 |
ALK一个指标医院要900多 ...

& x3 b6 k7 \# O平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
1 u! ^+ C9 x( x; U4 K- k& Z3 b5 A  F5 l- E! H2 o$ A2 o4 P
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表